Both Chloroquine and Lopinavir/Ritonavir Are Ineffective for COVID-19 Treatment and Combined Worsen the Pathology: A Single-Center Experience with Severely Ill Patients클로로퀸과 로피나비르/리토나비르는 모두 COVID-19 치료에 효과가 없으며 병용하면 병리학이 악화됩니다: 중증 환자를 대상으로 한 단일 센터 경험Research Article Published on 2021-02-062022-09-10 Journal: BioMed Research International [Category] 치료제, [키워드] Administered antimalarial drug Antimalarial drugs Antiviral antiviral drugs C-reactive protein carried Chloroquine circulating Combined Comorbidities Complete COVID-19 COVID-19 therapeutics CRP D-dimer decrease dimer drug Effectiveness ENhance experience ferritin ferritin levels Hospitalization Ill Ineffective knowledge Lactate lactate dehydrogenase LDH leukocytes Lopinavir Lopinavir/ritonavir Lymphocytes Mortality neutrophil off-label off-label use parameters Patient reduce researcher Ritonavir Safe SARS-CoV-2 severely ill patient severely ill patients standard treatment therapeutic option therapeutic options treat treating COVID-19 Treatment [DOI] 10.1155/2021/8821318 PMC 바로가기 [Article Type] Research Article
Both Chloroquine and Lopinavir/Ritonavir Are Ineffective for COVID-19 Treatment and Combined Worsen the Pathology: A Single-Center Experience with Severely Ill PatientsResearch Article Published on 2021-02-062022-10-27 Journal: BioMed Research International [Category] [키워드] Administered antimalarial drug Antiviral antiviral drugs C-reactive protein carried Chloroquine circulating Combined Comorbidities Complete COVID-19 COVID-19 therapeutics CRP decrease drug Effectiveness ENhance experience ferritin ferritin levels Hospitalization Ill Ineffective knowledge lactate dehydrogenase LDH leukocytes Lopinavir/ritonavir Lymphocytes Mortality neutrophil off-label parameters Patient reduce researcher Safe SARS-CoV-2 severely ill patient severely ill patients standard treatment therapeutic option treat treating COVID-19 Treatment [DOI] 10.1155/2021/8821318 PMC 바로가기 [Article Type] Research Article
Both Chloroquine and Lopinavir/Ritonavir Are Ineffective for COVID-19 Treatment and Combined Worsen the Pathology: A Single-Center Experience with Severely Ill PatientsResearch Article Published on 2021-02-062022-10-27 Journal: BioMed Research International [Category] COVID-19, [키워드] Administered antimalarial drug Antiviral antiviral drugs C-reactive protein carried Chloroquine circulating Combined Comorbidities Complete COVID-19 COVID-19 therapeutics CRP decrease drug Effectiveness ENhance experience ferritin ferritin levels Hospitalization Ill Ineffective knowledge lactate dehydrogenase LDH leukocytes Lopinavir/ritonavir Lymphocytes Mortality neutrophil off-label parameters Patient reduce researcher Safe SARS-CoV-2 severely ill patient severely ill patients standard treatment therapeutic option treat treating COVID-19 Treatment [DOI] 10.1155/2021/8821318 PMC 바로가기 [Article Type] Research Article
SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19SAveRUNNER: 약물 용도 변경을 위한 네트워크 기반 알고리즘 및 COVID-19에 적용Research Article Published on 2021-02-052022-09-02 Journal: PLoS Computational Biology [Category] MERS, 신약개발, 임상, 치료제, [키워드] (hydroxychloroquine Algorithm anti-IL6 anti-TNF applied Arthritis association cardiovascular diseases Chloroquine Clinical practice combination therapy Comorbidity coronavirus Coronavirus infections COVID-19 COVID-19 treatment COVID-19 treatments de novo disease disease-causing downstream drug Drug discovery drug target drugs effective drug effective drugs Efficiency enrichment analysis experiments Focusing gene set enrichment analysis Genetic heparin HIV human coronavirus Hydroxychloroquine in-silico include inhibitors knowledge lAbel lack Lopinavir malaria monoclonal antibodies monoclonal antibody network off-label Potential treatment predict Protein reduce Remdesivir remdesivir) repositioning rheumatoid arthritis rheumatoid arthritis) Ritonavir selected similarity thrombin Tocilizumab treat Vaccine variety worldwide pandemic PMC 바로가기 [Article Type] Research Article
Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19Observational Study Published on 2021-02-012022-10-05 Journal: International journal of clinical practice [Category] SARS, 임상, [키워드] age arrhythmia association calculated Cohort Combination combination therapy Comorbidities COVID-19 death determine drug electronic medical records evaluate evaluated Factor HCQ hospitalised patient hospitalized COVID-19 patient hospitalized patients implication in both groups in-hospital mortality incidence initial men novel coronavirus disease occurred off-label Patient patients with COVID-19 Prospective Study QT interval QTc QTc interval QTC prolongation retrospective significant increase significantly higher single-center therapy Treatment treatment regimens two group ventricular with COVID-19 ΔQTc [DOI] 10.1111/ijcp.13896 PMC 바로가기 [Article Type] Observational Study
[Fatal course of COVID-19 despite IL-6 receptor blockade in cytokine storm : Perimyocarditis and coagulopathy after administration of tocilizumab][사이토카인 폭풍에서 IL-6 수용체 차단에도 불구하고 코로나19의 치명적인 경과 : 토실리주맙 투여 후 심근주위염 및 응고병증]Case Reports Published on 2021-02-012022-09-11 Journal: Anaesthesist [Category] 진단, 치료제, [키워드] Administered administration Admission ARDS Azithromycin blockade can not Cardiac arrhythmia circulatory shock Clinical deterioration Coagulopathy Course COVID-19 criteria cytokine Cytokine storm diagnosed died ECMO Efficacy English Exacerbation hemodynamic instability hospital Hydroxychloroquin Hydroxychloroquine IL-6 receptor inflammation marker initiated lAbel male moderate multiorgan failure occurred off-label Patient patient selection Perimyocarditis Pneumonia Randomized controlled studies receptor receptor antagonist respiratory insufficiency second dose Shock Tage the patient Tocilizumab Treatment treatment with tocilizumab with COVID-19 worsened [DOI] 10.1007/s00101-020-00871-x PMC 바로가기 [Article Type] Case Reports
Tocilizumab in the Management of COVID-19: A Preliminary ReportCOVID-19 관리에서 Tocilizumab: 예비 보고서Observational Study Published on 2021-02-012022-09-12 Journal: The American journal of the medical sciences [Category] MERS, 임상, 진단, [키워드] acute respiratory distress Administered administration Admission age analyzed association average benefit Care collected Confirmed COVID-19 death evaluate hospital hospitalized patient ICU ICU admission IL-6 increased mortality intensive care interleukin-6 receptor likelihood mechanical ventilation monoclonal antibody Mortality Odds ratio off-label outcome outcomes overall mortality Patient patients with COVID-19 Philadelphia Pneumonia progression Prospective report Respiratory failure Retrospective analysis subject suggested syndrome Treatment Trial with COVID-19 [DOI] 10.1016/j.amjms.2020.11.005 PMC 바로가기 [Article Type] Observational Study
Plasma Concentrations and Safety of Lopinavir/Ritonavir in COVID-19 PatientsCOVID-19 환자에서 로피나비르/리토나비르의 혈장 농도 및 안전성Article Published on 2021-02-012022-09-11 Journal: Therapeutic drug monitoring [Category] 치료제, [키워드] absence Adverse drug reaction Adverse drug reactions antiviral activity average caution Concentration COVID-19 COVID-19 patient disorders dosage drug reaction Efficacy expected HIV HIV treatment in vivo increase in Inflammation Inflammatory interquartile lAbel limit Lopinavir Lopinavir/ritonavir moderate-to-severe COVID-19 Occurrence off-label off-label use one patient Patient plasma concentration plasma concentrations Previous studies reduced reported required Retrospective study Ritonavir Safety safety profile SARS-CoV-2 significantly suggested treated Treatment treatment for COVID-19 [DOI] 10.1097/FTD.0000000000000838 PMC 바로가기 [Article Type] Article
Surfactant therapy for COVID-19 related ARDS: a retrospective case–control pilot studyResearch Published on 2021-01-182022-10-28 Journal: Respiratory Research [Category] COVID-19, MERS, [키워드] acute respiratory distress acute respiratory distress syndrome administration Analysis ARDS ARDS patient Care cause comparable COVID-19 COVID-19 ARDS patient COVID-19 ARDS patients COVID-19 pandemic Cox regression death deplete dose Efficacy Evidence examined feasibility feasible FIVE Health lung mechanical ventilation mechanical ventilation duration Mortality not significant off-label pandemic Patient patients with COVID-19 PCR positive performed pilot study positive randomized clinical trial receiving reduce mortality reduction Result retrospective Safe subject Support supportive care surfactant Surfactant replacement therapy syndrome therapy for COVID-19 Treatment Ventilation [DOI] 10.1186/s12931-020-01603-w PMC 바로가기 [Article Type] Research
Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trialCOVID-19(COVID-AT)로 인한 급성 호흡 곤란 증후군 환자에서 동종 간엽 기질 세포의 효능을 평가하기 위한 이중 맹검, 무작위, 대조 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-01-062022-09-10 Journal: Trials [Category] MERS, 바이오마커, 임상, 치료제, [키워드] 1:1 24 hours 7-point ordinal scale acute respiratory distress acute respiratory distress syndrome Administered administration Admission Adult patient Adult patients Adverse Adverse drug reactions AEs age All trial participants all-cause mortality allergy Allogeneic ARDS assessment assigned baseline Biomarker blinded Blinding C-reactive protein carcinoma carcinoma in situ carried cellular chain change childbearing potential Chloroquine Clinical practice clinical status clinical trial coagulation test coagulation tests conducted Control control arm Course COVID COVID-19 CRF criteria CT scan cumulative incidence current Cytokines D-dimer Day death described determined by Diagnosis disease dissemination double-blind drug Duration ECMO Efficacy Efficacy and safety element eligible End endpoints enrolment EudraCT evaluate evaluate the effect event exclusion criteria Extracorporeal extracorporeal membrane oxygenation failure ferritin fibrosis FiO2 form GRADE grade 3 greater Haemodialysis handling hemofiltration history hospital Hospitalization hydroxy ICU ICU admission IMPROVE include inclusion criteria Informed consent intravenous Intravenous administration intravenous dose intubation Invasive mechanical ventilation invasive ventilation investigational medicinal product involved laboratory confirmation laboratory-confirmed SARS-CoV-2 infection lactation LDH less Level Local Lopinavir Lopinavir/ritonavir lung disorder lymphocyte marker Mechanical mechanical ventilation Medicine Medicines Mesenchymal stromal cells moderate to severe Mortality MSC negative pregnancy test neoplasm neutrophil neutrophil counts Non-invasive number objective occur off-label opinion Ordinal Scale organ oropharyngeal swab oropharyngeal swabs Other outcome oxygen oxygen saturation Oxygen therapy PaO2 PaO2/FiO2 ratio parameters participant Patient PCR percentage Placebo polymerase chain reaction Pregnancy primary endpoint product Production profile progression protocol Pulmonary embolism pulmonary fibrosis Pulmonary function tests randomised randomised controlled trial randomization Randomized Randomly Rapid antigen tests reaction receive recruitment Registered Remdesivir report respiratory Respiratory distress syndrome Resuscitation Ritonavir SAEs Sample size SARS-COV-2 infection secondary Secondary endpoints Sequential Organ Failure Assessment Serious Adverse Events SOFA Spain specificity specimen Sponsor Standard of care status stromal cell stromal cells Study protocol subpopulations supplemental oxygen supplementary material syndrome the cell the disease the patient the primary endpoint the WHO time Tocilizumab Tolerability Treatment treatment arm treatment for COVID-19 treatment group Treatment protocol Trial trial participant Trial registration unit website women worldwide pandemic written consent [DOI] 10.1186/s13063-020-04964-1 PMC 바로가기 [Article Type] Letter